Stock listing

Frankfurt:C17 Corvus Pharmaceuticals, Inc. Aktie

German listing (Frankfurt) of Corvus Pharmaceuticals, Inc. · home listing NASDAQ:CRVS

Follow Corvus Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Share price · FWB:C17

€8.65 EUR -0.79 (-8.4%)

Close on Oct 30, 2026

Day range
€8.65 – €8.65 EUROct 30, 2026
Market cap
€727.8M EURAt the close on Oct 30, 2026 · price × 84.12M shares outstanding
Corvus Pharmaceuticals, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:CRVS · Home$10.03 USD-0.20 (-2.0%)845,085$10.09$10.37$9.78$10.23Close on Oct 30, 2026
Frankfurt:C17€8.652 EUR-0.79 (-8.4%)—€8.652€8.652€8.652€9.442Close on Oct 30, 2026
Ticker
Frankfurt:C17
Asset type
Stock
Exchange
Frankfurt
Currency
EUR

What changed lately

Calls

Upcoming

  • Corvus Pharmaceuticals (NASDAQ:CRVS) Q3 2026 Earnings Call

    Thu, Nov 05, 2026 · 4:30 PM ET

    Register

Replays

  • Corvus Pharmaceuticals (NASDAQ:CRVS) Q2 2026 Earnings Call

    Thu, Aug 06, 2026 · 4:30 PM ET

    Watch Transcript

  • Corvus Pharmaceuticals (NASDAQ:CRVS) Q4 2025 Earnings Call

    Thu, Mar 12, 2026 · 4:30 PM ET

    Watch Transcript

  • Corvus Pharmaceuticals (NASDAQ:CRVS) Q3 2025 Earnings Call

    Tue, Nov 04, 2025 · 4:30 PM ET

    Watch Transcript

Latest news

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2026 Financial Results on November 5, 2026

Oct 29, 2026

Corvus Pharmaceuticals Announces Initiation of Phase 1b Clinical Trial of Soquelitinib for Patients with Hidradenitis Suppurativa

Sep 30, 2026

Corvus Pharmaceuticals to Present at the 2026 Cantor Global Healthcare Conference

Sep 3, 2026

Corvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma Trial

Aug 27, 2026

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results

Aug 6, 2026

Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2026 Financial Results on August 6, 2026

Jul 30, 2026

Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China

Jun 9, 2026

Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference

May 20, 2026

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results

May 7, 2026

Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of Directors

Apr 23, 2026

All Corvus Pharmaceuticals, Inc. news

Decks

Corvus Pharmaceuticals, Inc. on 6ix

News releases
23 in the last 12 months · 123 in all · newest Oct 29, 2026 · oldest 2019
Calls
14 calls with a replay · 14 with a transcript · latest Aug 6, 2026
Decks
13 decks · latest Aug 6, 2026

Where Corvus Pharmaceuticals, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:CRVS · Home listingNASDAQUnited StatesUSD
gettex:C17gettexGermanyEUR
LS Exchange:A2AFXSLS ExchangeGermanyEUR
Lang & Schwarz:A2AFXSLang & SchwarzGermanyEUR
Tradegate:C17TradegateGermanyEUR
BOATS:CRVSBOATSUnited StatesUSD
Dusseldorf:C17DusseldorfGermanyEUR
Frankfurt:C17 · This pageFrankfurtGermanyEUR
Hamburg:C17HamburgGermanyEUR
Munich:C17MunichGermanyEUR
BX Swiss:C17BX SwissSwitzerlandCHF
Stuttgart:C17StuttgartGermanyEUR

Log in to ask 6ix AI your own questions about Corvus Pharmaceuticals, Inc.